Moreover, the protection against NAFLD in ARMCX3-KO mice was accompanied by less HFD-induced alanine aminotransferase (ALT) activity in plasma (Figure 1G) indicating reduced hepatocellular injury [18]. Here, ARMCX3 is linked to metabolic dysfunction-associated steatotic liver disease.